The melatonin agonist ramelteon attenuates bleomycin-induced lung fibrosis by suppressing the NLRP3/TGF-Β1/HMGB1 signaling pathway
Advances in Medical Sciences · 2023
DOI: 10.1016/j.advms.2023.09.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Medical Sciences, 2023. Verfasst von Pelin Aydin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey. Electronic address: hzekai@atauni.edu.tr. Hauptthemen laut MEDLINE: HMGB1 Protein, Melatonin, Pulmonary Fibrosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The possible effects of ramelteon, a melatonin receptor agonist on bleomycin-induced lung fibrosis were analyzed via transforming growth factor β1 (TGF-β1), the high mobility group box 1 (HMGB1) and Nod-like receptor pyrin domain-containing 3 (NLRP3) which are related to the fibrosis process. MATERIALS AND METHODS: Bleomycin (0.1 mL of 5 mg/kg) was administered by intratracheal instillation to induce pulmonary fibrosis (PF). Starting 24 h after bleomycin administration, a single dose of ramelteon was administered by oral gavage to the healthy groups, i.e. PF + RM2 (pulmonary fibrosis model with bleomycin + ramelteon at 2 mg/kg) and PF + RM4 (pulmonary fibrosis model with bleomycin + ramelteon at 4 mg/kg) at 2 and 4 mg/kg doses, respectively. Real-time polymerase chain reaction (real-time PCR) analyses, histopathological, and immunohistochemical staining were performed on lung tissues. Lung tomography images of the rats were also examined. RESULTS: The levels of TGF-β1, HMGB1, NLRP3, and interleukin 1 beta (IL-1β) mRNA expressions increased as a result of PF and subsequently decreased with both ramelteon doses (p < 0.0001). Both doses of ramelteon partially ameliorated the reduction in the peribronchovascular thickening, ground-glass appearances, and reticulations, and the loss of lung volume. CONCLUSIONS: The severity of fibrosis decreased with ramelteon application. These effects of ramelteon may be associated with NLRP3 inflammation cascade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey. Electronic address: hzekai@atauni.edu.tr.
- Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
- Department of Health Services Vocational School, Bayburt University, Bayburt, Turkey.
- Department of Pathology, Faculty of Veterinary Medicine, Ataturk University, Erzurum, Turkey.
- Department of Pathology, Faculty of Veterinary Medicine, Cumhurıyet University, Sıvas, Turkey.
- Department of Radiology, Faculty of Medicine, Atatürk University, Erzurum, Turkey.
Zitieren
APA
Aydin, P., Aksakalli-Magden, Z. B., Civelek, M. S., Karabulut-Uzuncakmak, S., Mokhtare, B., Ozkaraca, M., Alper, F., & Halici, Z. (2023). The melatonin agonist ramelteon attenuates bleomycin-induced lung fibrosis by suppressing the NLRP3/TGF-Β1/HMGB1 signaling pathway. Advances in Medical Sciences. https://doi.org/10.1016/j.advms.2023.09.004
Vancouver
Aydin P, Aksakalli-Magden ZB, Civelek MS, Karabulut-Uzuncakmak S, Mokhtare B, Ozkaraca M, et al. The melatonin agonist ramelteon attenuates bleomycin-induced lung fibrosis by suppressing the NLRP3/TGF-Β1/HMGB1 signaling pathway. Advances in Medical Sciences. 2023. doi:10.1016/j.advms.2023.09.004
BibTeX
@article{Aydin2023,
author = {Aydin, Pelin and Aksakalli-Magden, Zeynep B and Civelek, Maide S and Karabulut-Uzuncakmak, Sevgi and Mokhtare, Behzad and Ozkaraca, Mustafa and Alper, Fatih and Halici, Zekai},
title = {The melatonin agonist ramelteon attenuates bleomycin-induced lung fibrosis by suppressing the NLRP3/TGF-Β1/HMGB1 signaling pathway},
journal = {Advances in Medical Sciences},
year = {2023},
doi = {10.1016/j.advms.2023.09.004}
}
EUVIMED